OTCMKTS:IPSEYIPSEN S A/S Stock Price, Forecast & News

$19.92

0.00 (0.00 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$19.92

Now: $19.92▼

$19.92

50-Day Range

$14.40

MA: $17.46▼

$19.65

52-Week Range

$9.10

Now: $19.92▼

$34.30

Volume250 shs

Average Volume1,367 shs

Market Capitalization$6.68 billion

P/E Ratio10.54

Dividend YieldN/A

Beta1.26

Ipsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity. The company also provides NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; and Increlex used for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; Fortrans for the treatment of intestinal cleaning; Eziclen, an osmotic laxative indicated for the cleaning of bowel; Etiasa for the treatment of inflammatory bowel diseases; and Tanaka for mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for the treatment of gout; Prontalgine, an analgesic for the treatment of moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. Ipsen S.A. has a strategic agreement with Arix Bioscience plc to develop and commercialize various therapies. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for IPSEN S A/S.

2.3 Community Rank

Outperform Votes
IPSEN S A/S has received 166 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
IPSEN S A/S has received 190 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
IPSEN S A/S has received 53.37% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about IPSEN S A/S and other stocks. Vote “Outperform” if you believe IPSEY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IPSEY will underperform the S&P 500 over the long term. You may vote once every thirty days.

1.7 Dividend Strength

Dividend Yield
IPSEN S A/S does not currently pay a dividend.
Dividend Growth
IPSEN S A/S does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of IPSEN S A/S is 10.58 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, IPSEN S A/S will have a dividend payout ratio of 9.39 % next year. This indicates that IPSEN S A/S will be able to sustain or increase its dividend.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IPSEN S A/S insiders have not sold or bought any company stock.

1.9 Earnings and Valuation

Earnings Growth
Earnings for IPSEN S A/S are expected to grow by 7.04% in the coming year, from $1.99 to $2.13 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IPSEN S A/S is 10.54, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 14.78.
Price to Earnings Ratio vs. Sector
The P/E ratio of IPSEN S A/S is 10.54, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 17.78.
Price to Book Value per Share Ratio
IPSEN S A/S has a P/B Ratio of 3.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.17 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Diagnostic substances

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:IPSEY

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.ipsen.com

Phone33-01-58-33-50-00

Debt

Debt-to-Equity RatioN/A

Current Ratio0.93

Quick Ratio0.78

Price-To-Earnings

Trailing P/E Ratio10.54

Forward P/E Ratio10.01

P/E GrowthN/A

Sales & Book Value

Annual Sales$3.02 billion

Price / Sales2.21

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.86 per share

Price / Book3.40

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees5,700

Outstanding Shares335,180,000

Market Cap$6.68 billion

Next Earnings DateN/A

OptionableNot Optionable

Receive IPSEY News and Ratings via Email

Sign-up to receive the latest news and ratings for IPSEY and its competitors with MarketBeat's FREE daily newsletter.

IPSEN S A/S (OTCMKTS:IPSEY) Frequently Asked Questions

How has IPSEN S A/S's stock been impacted by COVID-19 (Coronavirus)?

IPSEN S A/S's stock was trading at $14.4150 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IPSEY shares have increased by 38.2% and is now trading at $19.92. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of IPSEN S A/S?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IPSEN S A/S in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for IPSEN S A/S.

Has IPSEN S A/S been receiving favorable news coverage?

News stories about IPSEY stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. IPSEN S A/S earned a news impact score of -3.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutIPSEN S A/S.

Who are some of IPSEN S A/S's key competitors?

Some companies that are related to IPSEN S A/S include IDEXX Laboratories (IDXX), Immunomedics (IMMU), Quidel (QDEL), Neogen (NEOG), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Heska (HSKA), Meridian Bioscience (VIVO), Quotient (QTNT), Lantheus (LNTH), Vermillion (VRML), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT) and Celldex Therapeutics (CLDX). View all competitors.

Who are IPSEN S A/S's key executives?

IPSEN S A/S's management team includes the following people:

Mr. David D. Meek, CEO & Director (Age 56)
Mr. Aymeric Le Chatelier, Exec. VP & CFO (Age 50)
Dr. Aidan Murphy, Exec. VP of Technical Operations (Age 53)
Dr. Alexandre P. Lebeaut, Exec. VP of R&D and Chief Scientific Officer (Age 62)
Ms. Eugenia Litz, VP of Investor Relations

What is IPSEN S A/S's stock symbol?

IPSEN S A/S trades on the OTCMKTS under the ticker symbol "IPSEY."

How do I buy shares of IPSEN S A/S?

Shares of IPSEY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IPSEN S A/S's stock price today?

One share of IPSEY stock can currently be purchased for approximately $19.92.

How big of a company is IPSEN S A/S?

IPSEN S A/S has a market capitalization of $6.68 billion and generates $3.02 billion in revenue each year. The company earns $-56,780,000.00 in net income (profit) each year or $1.89 on an earnings per share basis. IPSEN S A/S employs 5,700 workers across the globe.

What is IPSEN S A/S's official website?

The official website for IPSEN S A/S is www.ipsen.com.

How can I contact IPSEN S A/S?

IPSEN S A/S's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The company can be reached via phone at 33-01-58-33-50-00 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff